REG-Bioventix Plc: Trading Update & Notice of Results

BioventixAnnouncement

14/09/2022 07:15

Bioventix plc

(“Bioventix” or “the Company”)

Trading Update & Notice of Results

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, is pleased to announce a trading update for the year
ended 30 June 2022 (“FY2022”).

As announced in our interim results to 31 December 2021, we had a slow start
to the financial year. However, in the second half, we have seen an
improvement in performance and our trading result for FY2022 as a whole is
likely to be significantly ahead of market expectations.

This improvement reflects a degree of recovery from the pandemic effects
experienced since early 2020, and we hope that this recovery will prove to be
sustained and long-lasting. We are pleased that the roll-out of high
sensitivity troponin products, that are supported by our technology, has also
matched our expectations.

In addition, our results are reported in UK Sterling and the recent fall in
value of the UK Sterling against the US Dollar has had a positive effect.
Approximately 50% of our revenues are linked to US Dollars and royalties
received recently from customers in respect of our H2 sales have been
converted at more favourable exchange rates.

Notice of Results

Bioventix expects to release FY2022 results on 24 October 2022.

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer  Tel: 01252 728 001  
                                                                                             
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM    Tel: 020 7220 0500  

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the company's obligations under Article 17 of
MAR.



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved